Dose comparison of robustly optimized intensity modulated proton therapy (IMPT) vs IMRT and VMAT photon plans for testicular seminoma

References

• Znaor A, Skakkebaek NE, Rajpert-De Meyts E, et al. Global patterns in testicular cancer incidence and mortality in 2020. Int J Cancer. 2022;151(5):692–698. doi: 10.1002/ijc.33999.
   PubMed Web of Science ®Google Scholar
• Efstathiou JA, Paly JJ, Lu HM, et al. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. Radiother Oncol. 2012;103(1):12–17. doi: 10.1016/j.radonc.2012.01.012.
   PubMed Web of Science ®Google Scholar
• Mortensen MS, Bandak M, Kier MGG, et al. Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma, surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma. Cancer. 2017;123(7):1212–1218. doi: 10.1002/cncr.30458.
   PubMed Web of Science ®Google Scholar
• Mortensen MS, Lauritsen J, Gundgaard MG, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014;66(6):1172–1178. doi: 10.1016/j.eururo.2014.07.001.
   PubMed Web of Science ®Google Scholar
• Pierorazio PM, Cheaib JG, Tema G, et al. Performance characteristics of clinical staging modalities for early stage testicular germ cell tumors: a systematic review. J Urol. 2020;203(5):894–901. doi: 10.1097/JU.0000000000000594.
   PubMed Web of Science ®Google Scholar
• Pasalic D, Prajapati S, Ludmir EB, et al. Outcomes and toxicities of proton and photon radiation therapy for testicular seminoma. Int J Part Ther. 2020;7(2):11–20. doi: 10.14338/IJPT-20-00018.1.
   PubMedGoogle Scholar
• Bandak M, Lauritsen J, Johansen C, et al. Sexual function in a nationwide cohort of 2,260 survivors of testicular cancer after 17 years of followup. J Urol. 2018;200(4):794–800. doi: 10.1016/j.juro.2018.04.077.
   PubMed Web of Science ®Google Scholar
• Knap MM, Bentzen SM, Jens Overgaard J. Late neurological complications after irradiation of malignant tumors of the testis. Acta Oncol. 2007;46(4):497–503. doi: 10.1080/02841860601052752.
   PubMed Web of Science ®Google Scholar
• Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354–1365. doi: 10.1093/jnci/dji278.
   PubMedGoogle Scholar
• Kier MG, Hansen MK, Lauritsen J, et al. Second malignant neoplasms and cause of death in patients with germ cell cancer. A Danish nationwide cohort study. JAMA Oncol. 2016;2(12):1624–1627. doi: 10.1001/jamaoncol.2016.3651.
   PubMed Web of Science ®Google Scholar
• Simone CB, Kramer K, William P, et al. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys. 2012;82(1):242–249. doi: 10.1016/j.ijrobp.2010.11.021.
   PubMed Web of Science ®Google Scholar
• Teoh M, Clark CH, Whitaker S, et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84(1007):967–996. doi: 10.1259/bjr/22373346.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Mamalui-Hunter M, Mendenhall NP, et al. Improving the therapeutic ratio by using proton therapy in patients with stage I or II seminoma. Am J Clin Oncol. 2013;36(1):31–37. doi: 10.1097/COC.0b013e3182354b9e.
   PubMed Web of Science ®Google Scholar
• Maxwell R, Chang Y, Paul C, et al. Cancer control, toxicity, and secondary malignancy risks of proton radiation therapy for stage I-IIB testicular seminoma. Adv Radiat Oncol. 2023;8(5):101259. doi: 10.1016/j.adro.2023.101259.
   PubMedGoogle Scholar
• Wilder RB, Buyyounouski MK, Efstathiou JA, et al. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys. 2012;83(4):e445–e452. doi: 10.1016/j.ijrobp.2012.01.044.
   PubMed Web of Science ®Google Scholar
• Gay HA, Barthold HJ, O'Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012;83(3):e353–e362. doi: 10.1016/j.ijrobp.2012.01.023.
   PubMed Web of Science ®Google Scholar
• Jabbour SK, Hashem SA, Bosch W, et al. Upper abdominal normal organ contouring guidelines and atlas: a radiation therapy oncology group consensus. Pract Radiat Oncol. 2014;4(2):82–89. doi: 10.1016/j.prro.2013.06.004.
   PubMedGoogle Scholar
• Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model. 2011;8(1):27. doi: 10.1186/1742-4682-8-27.
   PubMed Web of Science ®Google Scholar
• Timlin C, Loken J, Kruse J, et al. Comparing second cancer risk for multiple radiotherapy modalities in survivors of Hodgkin lymphoma. Br J Radiol. 2021;94(1121):20200354.
   PubMed Web of Science ®Google Scholar
• Schneider U, Lomax A, Pemler P, et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther Onkol. 2006;182(11):647–652. doi: 10.1007/s00066-006-1534-8.
   PubMed Web of Science ®Google Scholar
• Groot HJ, Lubberts S, de Wit R, et al. Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. J Clin Oncol. 2018;36(24):2504–2513. doi: 10.1200/JCO.2017.77.4174.
   PubMed Web of Science ®Google Scholar
• Hellesnes R, Myklebust TÅ, Fosså SD, et al. Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort. J Clin Oncol. 2021;39(32):3561–3573. doi: 10.1200/JCO.21.00637.
   PubMed Web of Science ®Google Scholar
• Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958–1998. Radiat Res. 2007;168(1):1–64. doi: 10.1667/RR0763.1.
   PubMed Web of Science ®Google Scholar
• Schneider U, Hälg R. The impact of neutrons in clinical proton therapy. Front Oncol. 2015;5:235. doi: 10.3389/fonc.2015.00235.
   PubMed Web of Science ®Google Scholar
• Hälg RA, Schneider U. Neutron dose and its measurement in proton therapy—current state of knowledge. Br J Radiol. 2020;93(1107):20190412. doi: 10.1259/bjr.20190412.
   PubMed Web of Science ®Google Scholar
• Schneider U, Agosteo S, Pedroni E, et al. Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys. 2002;53(1):244–251. doi: 10.1016/s0360-3016(01)02826-7.
   PubMed Web of Science ®Google Scholar
• Gort EM, Beukema JC, Matysiak W, et al. Inter-fraction motion robustness and organ sparing potential of proton therapy for cervical cancer. Radiother Oncol. 2021;154:194–200. doi: 10.1016/j.radonc.2020.09.022.
   PubMed Web of Science ®Google Scholar
• Marks LB, Yoke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):10–19.
   PubMed Web of Science ®Google Scholar